Erectile dysfunction as an early biomarker of cardiovascular toxicity: Mechanisms and clinical implications

Review paper argues ED can show up 2-5 years before heart disease, or within months on certain cancer drugs

Journal: Microvascular Research | Published: 2026-04-18 | Type: Journal Article, Review | PMID: 42009193 Authors: Jaiswal Rahul, Devi Nikita, Chauhan Lakshman, Ahmad Sageer, Pandey Supriya, Tiwari Kartik, Yadav Ashok Kumar, Ali Asad, Jaiswal Rupali, Reetu (multiple pharmacy colleges, Uttar Pradesh and Karnataka, India) Funding/COI: Funding not listed; authors declare no competing interests

Summary

This is a narrative review, not a new study, arguing that erectile dysfunction can serve as an early warning sign of cardiovascular damage because penile arteries (1-2 mm) are smaller than coronary arteries (3-4 mm) and show endothelial injury first. The authors distinguish two patterns: ED tied to conventional risk factors (diabetes, hypertension) that precedes cardiovascular events by 2-5 years, versus drug-induced ED from cancer therapies that shows up within months to 2 years of starting treatment. They propose a five-step monitoring framework combining IIEF-5 questionnaires, cardiac biomarkers, ECG, and imaging, but this framework has not been tested in any clinical population.

Claims

• Penile cavernosal arteries (~1-2 mm) are smaller than coronary arteries (~3-4 mm), which the authors argue explains why endothelial dysfunction manifests there first
• In men with traditional cardiovascular risk factors, ED precedes overt cardiovascular events by 2-5 years
• Drug-induced ED from anthracycline chemotherapy, androgen deprivation therapy, tyrosine kinase inhibitors, VEGF inhibitors, and immune checkpoint inhibitors emerges within months to 2 years of treatment start
• Proposes a five-step framework: IIEF-5 screening, cardiovascular risk scoring augmented by NT-proBNP and high-sensitivity troponin, ECG-derived diastolic dysfunction indexing, and multimodality imaging (echocardiography with global longitudinal strain, coronary artery calcium scoring, carotid intima-media thickness)

Study Quality

This is a narrative review synthesizing existing mechanistic and epidemiological literature on the ED-cardiovascular disease link, a relationship that has been documented in the literature for over two decades (the "artery size hypothesis" itself predates this paper). The abstract contains no original data collection, no systematic search methodology description, no sample sizes, and no statistical results, meaning none of the numeric claims (the 2-5 year and months-to-2-year windows) can be independently weighed for strength of evidence from the abstract alone; they read as summary figures pulled from prior studies rather than this paper's own findings.

The proposed five-step clinical framework is presented as a synthesis recommendation, not something validated against outcomes data in this paper. No prospective or retrospective cohort was used to test whether the framework actually predicts cardiovascular events better than existing risk scores.

Red Flags

• No systematic review methodology reported (search strategy, inclusion/exclusion criteria, number of studies screened) despite covering multiple drug classes and mechanisms
• All ten authors are affiliated with pharmacy colleges in India rather than cardiology, urology, or oncology research centers, which is unusual for a paper making clinical monitoring recommendations
• The five-step monitoring framework is proposed but not validated in any patient cohort within this paper
• No original data; numeric claims (2-5 years, months to 2 years) are not traceable to specific cited studies in the abstract

Strengths

• Addresses a real and clinically relevant question: ED as a sentinel marker for cardiotoxicity from cancer therapies is an active area of cardio-oncology research
• Distinguishes two mechanistically distinct ED patterns (risk-factor-driven vs. drug-induced) rather than conflating them
• Covers a broad range of relevant drug classes (anthracyclines, ADT, TKIs, VEGF inhibitors, checkpoint inhibitors)
• No industry funding or declared conflicts of interest

Verdict

This is a review article synthesizing an already-established idea (ED as an early cardiovascular signal) rather than a study generating new evidence, and the abstract offers no methodology detail to judge how rigorously the underlying literature was selected. The proposed five-step monitoring framework is an interesting synthesis but is unvalidated speculation dressed up as a clinical protocol. Worth a skim if you want a mechanistic overview of drug-induced cardiotoxicity and ED overlap, not worth citing for the specific timeframes claimed without chasing down the primary sources.